46.91
-0.26 (-0.55%)
| Previous Close | 47.17 |
| Open | 47.60 |
| Volume | 13,457,201 |
| Avg. Volume (3M) | 19,164,506 |
| Market Cap | 69,724,921,856 |
| Price / Earnings (TTM) | 19.63 |
| Price / Earnings (Forward) | 14.45 |
| Price / Sales | 3.52 |
| Price / Book | 2.79 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2026 |
| Profit Margin | 11.58% |
| Operating Margin (TTM) | 20.09% |
| Diluted EPS (TTM) | 1.37 |
| Quarterly Revenue Growth (YOY) | 20.90% |
| Quarterly Earnings Growth (YOY) | 36.20% |
| Total Debt/Equity (MRQ) | 52.16% |
| Current Ratio (MRQ) | 1.45 |
| Operating Cash Flow (TTM) | 3.81 B |
| Levered Free Cash Flow (TTM) | 2.32 B |
| Return on Assets (TTM) | 5.28% |
| Return on Equity (TTM) | 9.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Boston Scientific Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.75 |
|
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Large Core |
| % Held by Insiders | 0.18% |
| % Held by Institutions | 93.22% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |